Stage IV Renal Cell Cancer Clinical Trial
Official title:
Phase 2 Trial of Sequential Bevacizumab Then Subcutaneous Interleukin-2 in Metastatic Renal Cancer
This phase II trial is studying how well giving bevacizumab together with interleukin-2 works in treating patients with metastatic kidney cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Interleukin-2 may stimulate the white blood cells to kill tumor cells. Giving bevacizumab together with interleukin-2 may kill more tumor cells.
PRIMARY OBJECTIVES:
I. Determine the frequency of major response in patients with metastatic renal cell cancer
treated with bevacizumab and interleukin-2.
SECONDARY OBJECTIVES I. Compare the median progression-free survival and median overall
survival of patients treated with this regimen with risk-stratified historical controls from
published risk models.
OUTLINE:
Patients receive bevacizumab IV over 30-90 minutes on day 1 in weeks 1, 3, 5, 7, 9, and 11.
Patients also receive interleukin-2 subcutaneously on days 1-5 in weeks 5-10. Treatment
repeats every 12 weeks for up to 2 courses in the absence of disease progression or
unacceptable toxicity. Patients with stable or responding disease then receive bevacizumab
alone in weeks 1, 3, 5, 7, 9, and 11. Courses with bevacizumab alone repeat every 12 weeks
in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed at 30 days and then every 3
months for at least 2 years.
PROJECTED ACCRUAL: Approximately 10-38 patients will be accrued for this study within 21
months.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01740154 -
Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer
|
N/A | |
Completed |
NCT00101114 -
Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer
|
Phase 2 | |
Completed |
NCT00078858 -
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
|
Phase 1/Phase 2 | |
Completed |
NCT03229278 -
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
|
Phase 1 | |
Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
Completed |
NCT01243359 -
Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies
|
Phase 1 | |
Completed |
NCT00278395 -
Vorinostat in Treating Patients With Kidney Cancer
|
Phase 2 | |
Terminated |
NCT00098618 -
Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
|
Phase 2 | |
Completed |
NCT00006486 -
Carboxyamidotriazole in Treating Patients With Metastatic Kidney Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01684397 -
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT02273752 -
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
|
Phase 2 | |
Completed |
NCT01265368 -
A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET)
|
Phase 1/Phase 2 | |
Completed |
NCT00408902 -
Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
|
Phase 2 | |
Completed |
NCT00005799 -
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
|
N/A | |
Completed |
NCT00019539 -
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
|
Phase 2 | |
Completed |
NCT02899078 -
Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT02944617 -
Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor
|
N/A | |
Completed |
NCT01727089 -
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
|
Phase 2 | |
Completed |
NCT00499135 -
Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT01943188 -
Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer
|
Phase 1 |